A Study of TG103 Injection in Overweight or Obesity

NCT05299697 · Unknown status

Last updated 2026-05-28

This clinical trial is testing the safety and effects of TG103 Injection in adults who are overweight or have obesity.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 195 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2022-05 · est. completion 2023-09

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05299697 ↗

Description as written by the study sponsor.

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of two dose levels of TG103 injection, a GLP-1 receptor agonist, in the management of overweight or obesity, to support dose selection for further development.

Treatments tested

TG103 15 mg Drug

Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
TG103 22.5 mg Drug

Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.
Placebo Drug

Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.

Main thing measured	Relative change from baseline in body weight at week 24
Sponsor	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions studied	Overweight or Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05299697 ↗